The global women’s healthcare market is expected to grow at a CAGR of ~9.78% from 2020 to reach USD 19.8 billion by 2027. The growth is mainly ascribed by the prevalence of chronic health disorders among women, government initiatives aimed to control population and prevention of unwanted pregnancies and R&D in women’s health products.  

Browse report overview on "Global Women’s Healthcare Market" at: https://www.sperresearch.com/report-store/Women-Health-Care.aspx

The global women’s healthcare market study provides market data for-by drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL and ORTHO TRI-CY LO (28), by application (hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, polycystic ovary syndrome, and other applications). The study also evaluates industry competitors and analyses the market at a regional and country level.

On the basis of drug, women’s healthcare market showed highest growth for Proila segment during the forecast period. The increased growth is accounted for the use in postmenopausal osteoporosis, prevalence of obesity in women and increasing population of older women.

By application, postmenopausal osteoporosis segment accounted for largest share of women’s healthcare market in 2020. The large market share of this segment can be attributed to increasing population of older women and introduction of various related drugs to cure menopausal osteoporosis. 

Don’t miss out on business opportunities in the "Global Women’s Healthcare Market". Request customized report as per your need and gain crucial industry insights that will help your business grow at: https://www.sperresearch.com/report-store/Women-Health-Care.aspx?custom=1

This research report analyses major geographies and provides a comprehensive analysis of North America (US, Canada), Europe (Germany, France, UK, Italy, Spain and Rest of Europe), Asia-Pacific (China, India, Japan, and RoAPAC), Rest of the world (Latin America, and Middle East & Africa). North America accounted for the largest share of the global women’s healthcare market due to the prevalence of poly cystic ovary syndrome & post-menopausal osteoporosis in the population, increasing expenditure on women’s health by governments. On the other hand, APAC is expected to grow at highest CAGR. The growth is mainly driven by rising awareness, prevalence of disorders such as infertility, osteoarthritis and other related diseases in women. 

The major players operating in the global women’s healthcare market are